The Montelukast is a leukotrine receptor antagonist (LTRA) used for the maintenance treatment of asthma, chronic asthma attacks and to relieve symptoms of seasonal allergies. Montelukast biological half life is 2.5 to 5.5 hrs there by decreasing bioavailability upto 64%. So, in order to improve the bioavailability and efficacy, we have prepared buccal films of montelukast. In the present research work, buccal films were prepared using mucoadhesive polymers like HPMC (K4M), HPMC (50cps), HPMC (5 cps), Eudragit RL-100 and PVP K-30 by Solvent Casting technique. Buccal films were characterized for number of parameters like physical appearance and surface texture, weight uniformity, thickness, folding endurance, swelling index, surface pH, drug content uniformity, in vitro residence time, bursting strength, drug–excipients interaction study, and in vitro drug release study. All the prepared films were smooth surface and elegant texture. All the prepared films are weighing in between 26.33 to 37.66 mg. The thickness of the films was in the range of 0.246 to 0.373 mm. Folding endurance was in the range of 259 to 289. Swelling index in the range of 29.81 to 43.48 %. Surface pH was in the range of 6.00 to 6.83 pH. Drug content uniformity study showed uniform dispersion of the drug throughout the formulation in the range of 94.33 to 98.33 %. The in vitro residence time for all the films is in between 3.13 to 5.50 hrs. The bursting strength of films is in the range of 6.533 to 4.366 Kg/cm2. FT-IR studies revealed that, there was no incompatibility of the drug with the excipients used. In vitro drug release studies in the range of 67.35 to 93.62 at the end of 8th hrs.

Two simple and sensitive visible Spectrophotometric methods [I and II] have been developed for the quantitative estimation of Sparfloxacin in bulk and Pharmaceutical dosage forms. Method-I is based on ion-pair complex formation between Spar floxacin and Bromocresol purple, which shows yellow color and gives maximum absorption at 410.0 nm and obeys Beer’s law in the concentration range of 5-25 µg/ml. Method-II is bas ed on ion-pair complex formation between Sparfloxacin and Bromocresol green, which shows yel low color and gives maximum absorption at 420.0 nm and obeys Beer’s law in the concentrati on range of 5-25 µg/ml.

NA

Type II diabetes mellitus is a chronic metabolic di sorder and PPARs were found to be better targets in lowering glucose levels. Here, we report a computer-aided drug design approach to screen various chalcones, designed using substituted benza ldehydes and acetophenones from e-molecule library, as possible PPAR gamma agonists using Mole gro Virtual Docker software. Based on the dock scores and molecular weight comparisons of top 50 compounds from a designed data set of 2500 chalcones, compound 17_37 displayed a dock sco re of -230.10 kcal/mol with a maximum of 11 H-bond interactions.